Bausch + Lomb, Novaliq Eye-Drop Treatment's New Drug Application Accepted by FDA

 Bausch + Lomb Corp. said Tuesday that the U.S. Food and Drug Administration has accepted its new drug application for an eye drop to treat the symptoms of dry eye disease.

The eye-health company said the filing for investigational treatment NOV03 is in conjunction with biopharmaceutical company Novaliq GmbH.

The clinical development program for NOV03 have shown statistically significant improvement in two Phase 3 studies, the company said.

"The approval would also mark a significant milestone for Bausch + Lomb, as the company's first FDA approval for a prescription medicine since becoming a publicly traded company earlier this year," Chief Executive Joseph C. Papa said.

https://www.marketscreener.com/quote/stock/BAUSCH-LOMB-CORPORATION-137315071/news/Bausch-Lomb-Novaliq-Eye-Drop-Treatment-s-New-Drug-Application-Accepted-by-FDA-41703983/